Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, prolonged high-dose steroid treatment in rats caused several pathological changes, some of which regressed, particularly improvements in mammary gland tumors and pituitary-related symptoms, after stopping treatment.

Generic topical and transdermal systems usually cause minimal irritation or sensitization.

This article discusses oral spironolactone therapy for female patients with acne, hirsutism, or androgenic alopecia and reports no new clinical results.

In this study, spironolactone treatment reduced hair growth in 17 out of 30 patients with hirsutism, but was less effective compared to cyproterone acetate–estrogen therapy.

This study found that low doses of leuprolide effectively suppressed serum estradiol and LH response, while higher doses were needed to suppress testosterone and reduce hair growth in hirsute women.

This study suggests that combination drug therapy with spironolactone and either oral contraceptives or dexamethasone effectively manages unresponsive hirsutism, with eight of nine patients achieving satisfactory clinical responses.

This study reported that Diane-35 treatment over 6-9 months reduced hair loss, hair thinning, and seborrhoea in women with androgenetic alopecia.

In this study of a postmenopausal woman with hyperandrogenism, GnRH agonist treatment significantly reduced testosterone levels, suggesting the androgen excess was ovarian in origin and indicating the potential of using GnRH agonists as a conservative treatment option when surgery is not feasible.

Among women with polycystic ovary syndrome, this study found that oral contraceptives containing 20 μg ethinyl estradiol had similar effects on androgen levels as those containing 30 μg.

This article reviews the contraceptive agent Depo-Provera, discussing its effectiveness, potential side effects, and safety concerns, but reports no new clinical results.

This review evaluates the use of 5α-reductase inhibitors in feminising hormone therapy, finding their additive feminising benefits unclear due to their specific action on testosterone conversion, with concerns highlighted regarding limited supporting evidence and safety signals, particularly for psychiatric and sexual effects.

This study found that both Diane 35 plus spironolactone and Diane 35 plus finasteride were equally effective and safe for treating hirsutism and acne in Indian women over a 12-month period.

Certain enzymes react strongly with some hormones in rat skin during hair growth, mainly in sebaceous glands and hair sheaths.

This study found that a combination of spironolactone and oral contraceptive pills may improve hirsutism and hormonal profiles in women, although some experienced side effects such as persistent nausea.

This study found that spironolactone significantly reduced hair growth in hirsute women, with noticeable effects in 3-5 months, and decreased serum testosterone levels in all participants.

This study reviewed various dermatological conditions associated with oral contraceptive use, highlighting increased pigmentation, decreased sebum production, and changes in hair growth, among other effects.

The new compounds may be more effective and cheaper than current treatments for conditions like baldness.

This brief report discusses spironolactone used as a treatment for hirsutism in a hyperandrogenic woman, offering no new clinical findings and focusing on its antiandrogenic properties.

This study found that continuous use of loop diuretics may double the rate of bone loss in elderly men compared to intermittent or non-use.

The medicine Diane is effective in treating hair loss, severe acne, and excessive hair growth.

This study found that several synthesized pregnane derivatives exhibited significant inhibitory effects on testosterone conversion to dihydrotestosterone and reduced related androgenic parameters in multiple pharmacological models.

This article reviews hair loss associated with oral contraceptive use and suggests that while diffuse effluvium is usually harmless, androgenetic alopecia caused by certain contraceptive types requires a change in medication; no new clinical results are reported.

This review found limited evidence on the effectiveness of different antiandrogens for feminization in transgender women, suggesting cyproterone acetate, leuprolide, and medroxyprogesterone acetate may better suppress testosterone than spironolactone or estradiol alone.

This review found that women with idiopathic hirsutism may have increased 5α-reductase activity, as indicated by elevated levels of a dihydrotestosterone-reduced metabolite, but more research is needed to confirm its clinical relevance as a biomarker.

This article discusses the availability of data from TriNetX for research purposes and reports no new findings.

In this retrospective study, cyproterone acetate treatment in late-pubertal trans-girls was found to be generally safe and led to mild feminizing effects, with more rapid feminization occurring when combined with estrogens.

This phase 2 trial found that SM04554, a Wnt signaling modulator, was well-tolerated and increased follicle counts in males with androgenetic alopecia, suggesting potential for promoting hair growth.

This study found that Spironolactone-loaded ethosomal gels provided superior skin permeation and deposition compared to niosomal gels in rabbit skin, suggesting that ethosomal gels could be a promising formulation for further clinical studies on treating androgenic alopecia.

In this study, a topical lotion containing Redensyl and Sepicontrol A5 demonstrated effectiveness for treating androgenetic alopecia over 24 weeks, with 73.1% of users seeing moderate improvement and notable increases in hair cycle ratios, alongside enhanced quality of life and satisfaction.